Current State of Pediatric Heart Failure
Pediatric heart failure (HF) represents an important cause of morbidity and mortality in childhood. There is an overlapping relationship of HF, congenital heart disease, and cardiomyopathy. The goal of treatment of HF in children is to maintain stability, prevent progression, and provide a reasonabl...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Children |
Subjects: | |
Online Access: | http://www.mdpi.com/2227-9067/5/7/88 |
id |
doaj-b25e3fc8fabe48e994c32e897b39e390 |
---|---|
record_format |
Article |
spelling |
doaj-b25e3fc8fabe48e994c32e897b39e3902021-04-02T01:26:02ZengMDPI AGChildren2227-90672018-06-01578810.3390/children5070088children5070088Current State of Pediatric Heart FailureBibhuti B. Das0Joe DiMaggio Children’s Heart Institute, Memorial Health Care System, Hollywood, FL 33021, USAPediatric heart failure (HF) represents an important cause of morbidity and mortality in childhood. There is an overlapping relationship of HF, congenital heart disease, and cardiomyopathy. The goal of treatment of HF in children is to maintain stability, prevent progression, and provide a reasonable milieu to allow somatic growth and optimal development. Current management and therapy for HF in children are extrapolated from treatment approaches in adults. There are significant barriers in applying adult data to children because of developmental factors, age variation from birth to adolescence, and differences in the genetic expression profile and β-adrenergic signaling. At the same time, there are significant challenges in performing well-designed drug trials in children with HF because of heterogeneity of diagnoses identifying a clinically relevant outcome with a high event rate, and a difficulty in achieving sufficient enrollment. A judicious balance between extrapolation from adult HF guidelines and the development of child-specific data on treatment represent a wise approach to optimize pediatric HF management. This approach is helpful as reflected by the increasing role of ventricular assist devices in the management of advanced HF in children. This review discusses the causes, epidemiology, pathophysiology, clinical manifestations, conventional medical treatment, clinical trials, and the role of device therapy in pediatric HF.http://www.mdpi.com/2227-9067/5/7/88pediatric heart failureadvanced heart failureventricular assist devicemechanical circulatory support |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bibhuti B. Das |
spellingShingle |
Bibhuti B. Das Current State of Pediatric Heart Failure Children pediatric heart failure advanced heart failure ventricular assist device mechanical circulatory support |
author_facet |
Bibhuti B. Das |
author_sort |
Bibhuti B. Das |
title |
Current State of Pediatric Heart Failure |
title_short |
Current State of Pediatric Heart Failure |
title_full |
Current State of Pediatric Heart Failure |
title_fullStr |
Current State of Pediatric Heart Failure |
title_full_unstemmed |
Current State of Pediatric Heart Failure |
title_sort |
current state of pediatric heart failure |
publisher |
MDPI AG |
series |
Children |
issn |
2227-9067 |
publishDate |
2018-06-01 |
description |
Pediatric heart failure (HF) represents an important cause of morbidity and mortality in childhood. There is an overlapping relationship of HF, congenital heart disease, and cardiomyopathy. The goal of treatment of HF in children is to maintain stability, prevent progression, and provide a reasonable milieu to allow somatic growth and optimal development. Current management and therapy for HF in children are extrapolated from treatment approaches in adults. There are significant barriers in applying adult data to children because of developmental factors, age variation from birth to adolescence, and differences in the genetic expression profile and β-adrenergic signaling. At the same time, there are significant challenges in performing well-designed drug trials in children with HF because of heterogeneity of diagnoses identifying a clinically relevant outcome with a high event rate, and a difficulty in achieving sufficient enrollment. A judicious balance between extrapolation from adult HF guidelines and the development of child-specific data on treatment represent a wise approach to optimize pediatric HF management. This approach is helpful as reflected by the increasing role of ventricular assist devices in the management of advanced HF in children. This review discusses the causes, epidemiology, pathophysiology, clinical manifestations, conventional medical treatment, clinical trials, and the role of device therapy in pediatric HF. |
topic |
pediatric heart failure advanced heart failure ventricular assist device mechanical circulatory support |
url |
http://www.mdpi.com/2227-9067/5/7/88 |
work_keys_str_mv |
AT bibhutibdas currentstateofpediatricheartfailure |
_version_ |
1724175227475197952 |